Review ArticleNatriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society
Section snippets
Writing Committee Composition
The HFSA, the Heart Failure Association (HFA) of the ESC, and the JHFS selected the members of the writing committee, which consisted of 28 individuals with domain expertise in biomarkers and management of HF.
Consensus Development
On November 6, 2021, HFA, HFSA and JHFS convened a consensus conference to develop a paper on Natriuretic peptides: Role in the diagnosis and management of heart failure. The work of the writing committee was accomplished via a series of Web conference meetings, along with extensive e-mail
History and Basic Research: Discovery, Production and Cardiovascular Protection
Natriuretic peptide research began in 1956 with the discovery by Kisch of electron-dense granules named atrial-specific granules.4 Twenty years later, in 1981, DeBold found diuretic and vasodilating activity in atrial extract.5 At the end of 1983 and the beginning of 1984, DeBold and Matsuo and Kangawa succeeded in the isolation and identification of amino acid's primary structure independently.6 They also discovered 2 peptides, brain (B-type) natriuretic peptide (BNP) and C-type natriuretic
Diagnostic and Prognostic Implications in Acute and Chronic Settings
Accurate diagnosis and prognosis are essential for optimizing medical care for serious cardiovascular conditions such as HF. Natriuretic peptides play a central role in both the diagnosis of HF as well as in the accurate assessment of short- and long-term prognosis. Given that HF is a clinical syndrome, characterized by a collection of recognizable signs and symptoms, additional diagnostics are of high potential value. Prior frameworks for the diagnosis of ambulatory patients with HF, such as
The Role of Incorporation in Clinical Trials
Natriuretic peptide concentrations have been increasingly incorporated in eligibility criteria for clinical trials involving patients with HF. In this implementation, they serve at least 4 roles. First, natriuretic peptides provide a readily obtained, objective laboratory sign corroborating the diagnosis of HF and are particularly useful in acute HF and HFpEF trials where confounding diseases are more prominent in the presentation (eg, dyspnea from chronic obstructive pulmonary disease
Considerations in Therapeutic Approach
Guidelines from several leading HF societies all provide a Class I recommendation for measuring BNP or NT-proBNP for diagnosis or prognosis assessment in the management of chronic HF.2,3,59 The value of BNP/NT-proBNP for that purpose is, thus, widely acknowledged. However, arguments remain about the usefulness of BNP/NT-proBNP as a guide for medical treatment. Several clinical trials testing relatively small samples assessed the efficacy of BNP-guided therapy and had mixed results, although
Gaps in Knowledge and Future Directions
Despite the primacy of BNP and NT-proBNP as the biomarker standard for predicting prognosis in HF, important caveats regarding their use exist; addressing such questions might be expected to inform newer or more nuanced use of these important biomarkers.
These may be summarized into 3 main areas: (1) mechanistic insights, (2) implications for therapeutic approach, and (3) understanding the role of natriuretic peptides beyond the cardiovascular system.
Conclusion
This statement provides current evidence about the role of natriuretic peptides in the diagnosis and management of HF. It is expected to be scientifically and clinically relevant, with the ability to be of great value. Natriuretic peptides have universal applicability globally and high diagnostic, therapeutic and prognostic validity. We envision that this statement concerning the role of natriuretic peptides in the diagnosis and management of HF may be used by health care professionals in HF,
Take-home Visual Data
Disclosures
HT receives consultancy fees from Boehringer Ingelheim, Bayer Yakuhin, Novartis Pharma, Ono Pharmaceutical, Astra-Zeneca; remuneration from MSD, Astellas Pharma, Pfizer Japan, Bristol-Myers Squibb Company, Otsuka Pharmaceutical, Daiichi Sankyo, Mitsubishi Tanabe Pharma, Boehringer Ingelheim, Takeda Pharmaceutical, Bayer Yakuhin, Novartis Pharma, Kowa Pharmaceutical, Teijin Pharma; manuscript fees from Medical View, Nippon Rinsho; research funding from Actelion Pharmaceuticals Japan, Japan
Role of Funding Source
None.
References (110)
- et al.
A rapid and potent natriuretic response to intravenous injection of atrial myocardial extract in rats
Life Sci
(1981) - et al.
Purification and complete amino acid sequence of alpha-human atrial natriuretic polypeptide (alpha-hANP)
Biochem Biophys Res Commun
(1984) - et al.
Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT): a multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath
J Am Coll Cardiol
(2004) - et al.
Prevalence, predictors and clinical outcome of residual congestion in acute decompensated heart failure
Int J Cardiol
(2018) - et al.
Discharge BNP is a stronger predictor of 6-month mortality in acute heart failure compared with baseline BNP and admission-to-discharge percentage BNP reduction
Int J Cardiol
(2016) - et al.
Predictors of six-month mortality in BNP-matched acute heart failure patients
Am J Cardiol
(2015) - et al.
BNP-response to acute heart failure treatment identifies high-risk population
Heart Lung Circ
(2020) - et al.
Unexpectedly low natriuretic peptide levels in patients with heart failure
JACC Heart Fail
(2021) - et al.
Disproportionately low BNP levels in patients of acute heart failure with preserved vs. reduced ejection fraction
Int J Cardiol
(2021) - et al.
B-type natriuretic peptide and prognosis in heart failure patients with preserved and reduced ejection fraction
J Am Coll Cardiol
(2013)
B-type natriuretic peptide during treatment with sacubitril/valsartan: The PARADIGM-HF trial
J Am Coll Cardiol
Natriuretic peptide-based inclusion criteria in a heart failure clinical trial: Insights from COMMANDER HF
JACC Heart Fail
Prognostic importance of NT-proBNP and effect of empagliflozin in the EMPEROR-reduced trial
J Am Coll Cardiol
Effects of sacubitril/valsartan on N-terminal pro-B-type natriuretic peptide in heart failure with preserved ejection fraction
JACC Heart Fail
Detection and management of geographic disparities in the TOPCAT trial: Lessons learned and derivative eecommendations
JACC Basic Transl Sci
Should enrichment with natriuretic peptide levels be mandatory in global clinical trials?
JACC Heart Fail
Natriuretic peptides as biomarkers of treatment response in clinical trials of heart failure
JACC Heart Fail
N-terminal pro-B-type natriuretic peptide and clinical outcomes: vericiguat heart failure with reduced ejection fraction study
JACC Heart Fail
Natriuretic peptide response and outcomes in chronic heart failure with reduced ejection fraction
J Am Coll Cardiol
Rationale and design of the Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure Trial (ASCEND-HF)
Am Heart J
Learning from recent trials and shaping the future of acute heart failure trials
Am Heart J
Natriuretic peptides as inclusion criteria in clinical trials: a JACC: Heart Failure position paper
JACC Heart Fail
Haemodynamic effects of atrial peptide infusion in heart failure
Lancet
Effect of intravenous carperitide versus nitrates as first-line vasodilators on in-hospital outcomes in hospitalized patients with acute heart failure: Insight from a nationwide claim-based database
Int J Cardiol
A test in context: Neprilysin: Function, inhibition, and biomarker
J Am Coll Cardiol
Prognostic implications of changes in N-terminal pro-B-type natriuretic peptide in patients with heart failure
J Am Coll Cardiol
Early B-type natriuretic peptide change in HFrEF patients treated with sacubitril/valsartan: a pooled analysis of EVALUATE-HF and PROVE-HF
JACC Heart Fail
Atrial natriuretic peptide and treatment with sacubitril/valsartan in heart failure with reduced ejection fraction
JACC Heart Fail
NT-probnp goal achievement is associated with significant reverse remodeling and improved clinical outcomes in HFrEF
JACC Heart Fail
Atrial natriuretic peptide and treatment with sacubitril/valsartan in heart failure with reduced ejection fraction
JACC Heart Fail
Multiple cardiac biomarker testing among patients with acute dyspnea from the ICON-RELOADED study
J Card Fail
Selective upregulation of cardiac brain natriuretic peptide at the transcriptional and translational levels by pro-inflammatory cytokines and by conditioned medium derived from mixed lymphocyte reactions via p38 MAP kinase
J Mol Cell Cardiol
Possible association between body temperature and B-type natriuretic peptide in patients with cardiovascular diseases
J Card Fail
2022 AHA/ACC/HFSA guideline for the management of heart failure
J Cardiac Fail
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
Eur Heart J
JCS 2017/JHFS 2017 guideline on diagnosis and treatment of acute and chronic heart failure - digest version
Circ J
Electron microscopy of the atrium of the heart. I. Guinea pig
Exp Med Surg
A new natriuretic peptide in porcine brain
Nature
A membrane form of guanylate cyclase is an atrial natriuretic peptide receptor
Nature
Selective activation of the B natriuretic peptide receptor by C-type natriuretic peptide (CNP)
Science
Regulator of G-protein signaling subtype 4 mediates antihypertrophic effect of locally secreted natriuretic peptides in the heart
Circulation
Atrial natriuretic peptide locally counteracts the deleterious effects of cardiomyocyte mineralocorticoid receptor activation
Circ Heart Fail
Neprilysin and natriuretic peptide regulation in heart failure
Curr Heart Fail Rep
Natriuretic peptide metabolism, clearance and degradation
FEBS J
Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics
Eur Heart J
Natriuretic peptide-guided management in heart failure
J Cardiovasc Med
Heart Failure Association of the European Society of Cardiology practical guidance on the use of natriuretic peptide concentrations
Eur J Heart Fail
Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: Findings from the EVEREST trial
Eur Heart J
Acute heart failure congestion and perfusion status: impact of the clinical classification on in-hospital and long-term outcomes; insights from the ESC-EORP-HFA Heart Failure Long-Term Registry
Eur J Heart Fail
Admission, discharge, or change in B-type natriuretic peptide and long-term outcomes: data from Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure (OPTIMIZE-HF) linked to Medicare claims
Circ Heart Fail
Cited by (9)
A novel method for distinction heart rate variability during meditation using LSTM recurrent neural networks based on visibility graph
2024, Biomedical Signal Processing and ControlImpact of age on the predictive value of NT-proBNP in patients with diabetes mellitus stabilised after an acute coronary syndrome
2024, Diabetes Research and Clinical PracticeCharacteristics and incidence of cardiac events across spectrum of age in cardiac sarcoidosis
2024, IJC Heart and VasculatureJCF Heart Failure Year-In-Review 2023… Shaping the Future of Heart Failure
2024, Journal of Cardiac FailureNatriuretic peptide testing strategies in heart failure: A 2023 update
2024, Advances in Clinical Chemistry
This article is copublished in J Cardiac Fail and Eur J Heart Fail.